Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Non-current Assets
All assets not expected to be converted to cash within one year.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 12.4% from a year ago
Total non-current assets stood at $84.08M at the end of Q1 FY2026, down 12.4% from a year earlier and down 0.5% from the prior quarter. Over 3 fiscal years it compounded at +188.1% a year.
Context
- Total non-current assets amounted to 27.6% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -12.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 84.53M USD
- Year-over-year change
- +143.2%
- 3-year CAGR
- +188.1%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.53M | +143.2% |
| FY2024 | 2024-12-31 | 34.76M | +172.9% |
| FY2023 | 2023-12-31 | 12.74M | +260.2% |
| FY2022 | 2022-12-31 | 3.54M | — |
Total Non-current Assets vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total non-current assets of $84.08M is the 5th highest of the 11 companies compared; the peer median is $65.99M.
- Its year-over-year change of -12.4% is the 10th highest of 11, against a peer median of +9.3%.
- Total non-current assets amounts to 27.6% of total assets for SION, versus a peer median of 14.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $644.02M | +510.1% | +2.8% | 54.7% | |
| Sep 2026 | $623.71M | -5.6% | +6.8% | 41.6% | |
| Mar 2026 | $140.33M | -7.7% | -3.2% | 35.8% | |
| Mar 2026 | $122.64M | +25.8% | +48.5% | 24.3% | |
| Mar 2026 | $84.08M | -12.4% | +188.1% | 27.6% | |
| Jun 2026 | $74.18M | -1.9% | +3.6% | 20.0% | |
| Sep 2026 | $57.8M | +31.1% | +11.3% | 8.0% | |
| Mar 2026 | $39.93M | +20.5% | +2.7% | 9.5% | |
| Sep 2026 | $27.73M | +42.6% | +152.2% | 5.5% | |
| Mar 2026 | $26.18M | -4.6% | +0.1% | 2.5% | |
| Jun 2026 | $5.49M | -23.5% | +0.7% | 1.0% | |
| Peer median (excluding SION) | $65.99M | +9.3% | +3.2% | 14.8% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.